A message to the Fragile X community from Dr. Dayno on behalf of the team at Harmony Biosciences:
Representatives from Harmony Biosciences will be attending the 19th International Fragile X Conference with us in Orlando, Florida. They are excited to come together with the Fragile X community to listen, learn, and help pave the way for brighter futures.
If you see a member of the Harmony Biosciences team, don’t hesitate to say “hello” and ask about about their commitment to the Fragile X community and advancing science and treatment options.
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Study: Behavioural and Emotional Outcomes in individuals with Neurodevelopmental Disorders (BEOND)
The Cerebra Network for Neurodevelopmental Disorders is conducting a survey to learn more about behaviour, social functioning, sleep, hyperactivity, mood, physical and mental health, as well as family functioning and wellbeing, and how these change over time.
Allos Pharma Inc. Receives FDA Guidance and Support for their Phase 3 Trial of Arbaclofen in Fragile X Syndrome
Allos Pharma Inc. received invaluable FDA feedback on the design of their Phase 3 trial for arbaclofen for the treatment of Fragile X syndrome.